Quality of life in schizophrenia: Symptomatic markers of improvement over time.

Psychiatr Rehabil JMay 18, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Samuel M Murphy, Ana T Flores, Deepak K Sarpal et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial examined the relationship between symptom severity and quality of life (QoL) in 102 individuals with schizophrenia spectrum disorders over 18 months. Results indicated that improvements in total and psychological QoL were observed, with older individuals showing less improvement. Increased affective symptoms were linked to poorer QoL across multiple domains.

Key findings

  • Improvements in total and psychological QoL were observed over time across treatment groups.
  • Older individuals showed smaller QoL improvements compared to younger participants.
  • Increased affective symptomatology predicted diminished QoL in total, physical, psychological, and social domains.
  • Increased positive symptomatology was linked to poorer social relationships and environmental QoL.

Why it matters

Understanding the impact of symptom severity on QoL can guide clinicians in developing targeted interventions. Addressing affective symptoms may enhance QoL outcomes, particularly in younger patients, highlighting the need for tailored therapeutic approaches.

Source

PubMed · PMID 42149541Free full text on PubMed Central

Published in Psychiatr Rehabil J. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.